Zobrazeno 1 - 10
of 945
pro vyhledávání: '"Patricia LoRusso"'
Autor:
Toshio Shimizu, John Powderly, Albiruni Abdul Razak, Patricia LoRusso, Kathy D. Miller, Steven Kao, Sarah Kongpachith, Catherine Tribouley, Michelle Graham, Brian Stoll, Maulik Patel, Mohammad Sahtout, Martha Blaney, Rachel Leibman, Talia Golan, Anthony Tolcher
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
BackgroundTransforming growth factor (TGF)-ß1 is a pleiotropic cytokine that can promote tumor growth and suppress antitumor immune responses. Latent TGF-ß1 associates with glycoprotein-A repetition predominant (GARP) on the surface of regulatory T
Externí odkaz:
https://doaj.org/article/ecaf119bc00648e1807c616981421d5c
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 7 (2024)
The clinical research pipeline is critical to ensuring continued development of novel treatments that can offer patients with cancer safe and effective options. Unfortunately, progress has slowed since the COVID-19 pandemic due to uncovered, systemic
Externí odkaz:
https://doaj.org/article/411006a42ab147bf8691be7123885805
Autor:
Gail D. Lewis, Guangmin Li, Jun Guo, Shang-Fan Yu, Carter T. Fields, Genee Lee, Donglu Zhang, Peter S. Dragovich, Thomas Pillow, BinQing Wei, Jack Sadowsky, Douglas Leipold, Tim Wilson, Amrita Kamath, Michael Mamounas, M. Violet Lee, Ola Saad, Voleak Choeurng, Alexander Ungewickell, Sharareh Monemi, Lisa Crocker, Kevin Kalinsky, Shanu Modi, Kyung Hae Jung, Erika Hamilton, Patricia LoRusso, Ian Krop, Melissa M. Schutten, Renee Commerford, Mark X. Sliwkowski, Eunpi Cho
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-15 (2024)
Abstract Approved antibody-drug conjugates (ADCs) for HER2-positive breast cancer include trastuzumab emtansine and trastuzumab deruxtecan. To develop a differentiated HER2 ADC, we chose an antibody that does not compete with trastuzumab or pertuzuma
Externí odkaz:
https://doaj.org/article/654b41b090ea4a87be21fb42ec554dae
Autor:
Igor Puzanov, Shivaani Kummar, Sylvie Rottey, Patricia LoRusso, Kyriakos P Papadopoulos, Erika Hamilton, Josef Rüschoff, Fiona C Thistlethwaite, Nuria Kotecki, Christopher T Chen, Yvan LeBruchec, Jerzy Dyczkowski, Sara Samari, Marie Toukam, Joseph Boni, Karin Havenith, Serafino Pantano
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/e7bd7c5c673646de94e1c49e5f5e9618
Autor:
Antoni Ribas, Mohammed Milhem, Diwakar Davar, Patricia LoRusso, Zeynep Eroglu, Martin Gutierrez, Arindam Dhar, Carlos Becerra, Brian Di Pace, Tianli Wang, Hailei Zhang, Srimoyee Ghosh, Shyam Srivats, Theo Borgovan, Angela Waszak
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/124fe11cbcbd49b981727309c6d8f1f9
Autor:
Molly Malarkey, Alex P. Toscano, Mohammad Hadi Bagheri, Jeffrey Solomon, Laura B. Machado, Patricia LoRusso, Alice Chen, Les R. Folio, Priscila H. Goncalves
Publikováno v:
Heliyon, Vol 9, Iss 8, Pp e18680- (2023)
Rationale and objectives: Adenoid cystic carcinoma (ACC) is a rare salivary gland cancer. The vast majority of clinical trials evaluating systemic therapy efficacy in solid tumors use the Response Evaluation Criteria in Solid Tumors (RECIST) to measu
Externí odkaz:
https://doaj.org/article/4903f5df6a0143c682fa994fdeca01ec
Publikováno v:
Women in Academia Report; 5/1/2024, p1-1, 1p
Autor:
Stephane Champiat, Aurélien Marabelle, Aung Naing, Filip Janku, Patricia LoRusso, David Béchard, Elena Garralda, Vladimir Galvao, Peter Grell, Richard Sachse, Joachim Kiemle-Kallee
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
Externí odkaz:
https://doaj.org/article/007335cb94fa431999a325bb10f4dbd9
Autor:
Homer Adams, Patricia LoRusso, Juanita Lopez, Melissa Johnson, Özlem Türeci, Tahamtan Ahmadi, Ugur Sahin, Jessica Bauman, Daniel Haggstrom, Eleni Lagkadinou, Gaurav Bajaj, Yali Fu, Kristoffer Rohrberg
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
Externí odkaz:
https://doaj.org/article/5504cd1e2ae94610a037c158735c29e7